Erasca, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Erasca, Inc. (ERAS) had Debt Securities, Available-for-sale, Unrealized Loss Position of $288.67 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $288.67M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $258.32M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $15.65M.
- 2025-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $70.13M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position | Debt Securities, Available-for-sale, Unrealized Loss Position as first filed |
|---|---|---|
| 2026-06-30 | $288.67M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $258.32M 10-Q · filed 2026-05-11 | |
| 2025-09-30 | $15.65M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $70.13M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $29.00M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $135.02M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $44.81M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $230.66M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $162.48M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $105.55M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $199.56M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $177.92M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $79.23M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $107.90M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $88.00M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $70.20M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $61.20M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $67.99M 10-K · filed 2023-03-23 | $68.00M 10-K · filed 2022-03-24 |
| 2021-09-30 | $3.00M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $6.50M 10-Q · filed 2021-08-26 | |
| 2020-12-31 | $15.80M 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |